-
Part 1 | Session 1 ACC.24 Late-breaking Science Wrap Up
-
Part 1 | Session 2 What's Hot at ACC.24? Late-breaking Science Preview
-
Part 2 | Session 1 Late-Breaker Discussion: The EMPACT-MI Trial
-
Part 2 | Session 2 Late-Breaker Discussion: The AEGIS-II Trial
-
Part 2 | Session 3 Late-Breaker Discussion: The RELIEVE-HF Trial
-
Part 2 | Session 4 Late-Breaker Discussion: The ARISE-HF Trial
-
Part 3 | Session 2 Zilbesiran in Patients With Hypertension: KARDIA-2
-
Part 3 | Session 5 Chelation Therapy in Post-MI Pts with Diabetes: TACT2
-
Part 3 | Session 6 Semaglutide in Patients with HfpEF, Obesity and Diabetes: STEP HFpEF
-
Part 3 | Session 7 Self-Expanding vs Balloon Expandable TAVR: The SMART Trial
-
Part 3 | Session 9 Technology-Assisted Nonprescription Rosuvastatin: TACTiC
-
Part 3 | Session 10 Coronary Sinus Reducer in Refractory Angina: ORBITA COSMIC
-
Part 3 | Session 11 TAVI Vs SAVR in Patients with Severe Aortic Valve Stenosis: DEDICATE-DZHK6
-
Part 4 | Session 1 Artificial Intelligence in Cardiology: What You Need to Know in 2024
ACC.24 — Dr Harold E Bays, Science Officer for the Obesity Medicine Association, a member of the Board of Trustees of the Obesity Medicine Association, and a member of the Board of Directors of the American Society of Preventive Cardiology, joins us to highlight key information regarding weight loss medications in 2024.
Support: This is an independent interview conducted by Radcliffe Cardiology.
Recorded on-site at ACC.24, Atlanta.
Interviewer: Mirjam Boros
Editor: Jordan Rance
Videographer: Dan Brent, Tom Green, Mike Knight
Our recurring review series, View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offers a thorough examination of late-breaking and featured scientific findings, highlighting significant data.
To delve deeper into the pivotal clinical trial data unveiled at ACC 24, Dr Harriette Van Spall (McMaster University, Hamilton, CA) conducts interviews with the principal investigators as part of her Late-Breaker Discussion Series.
For brief and focused coverage of the essential data unveiled, our accessible Expert Interviews were conducted with a select group of faculty members, concentrating on the results, relevance, and implications for future research.
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
More from this programme
Part 1
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC.24.
Part 2
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principal investigators for discussion on selected late-breaking trials.
Part 3
Expert Interviews
Part 4
Highlights
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
Faculty Biographies

Harold Bays
Medical Director and President
Dr Harold Bays is Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center, US. He has served as a Principal Investigator for over 600 clinical trials of metabolic therapeutic interventions.
Dr Bays is Board Certified in Internal Medicine and Endocrinology and Metabolism, Diplomate of the American Board of Obesity Medicine, and a Diplomate of the American Board of Clinical Lipidology. He is a Fellow of the Obesity Medicine Association, The Obesity Society, the American College of Cardiology, the American Association of Clinical Endocrinologists, the National Lipid Association, and the American Society of Preventive Cardiology.
Dr Bays has written or served as a contributing author to over 350 scientific manuscripts and book chapters and authored/presented 100’s of scientific abstracts.
Comments